Lenalidomid Piramal (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑E3 ubiquitin ligase complex, leading to the targeted degradation of transcription factors Ikaros and Aiolos. This action modulates the immune system, inhibits new blood‑vessel formation, and exerts direct anti‑proliferative effects on malignant plasma and lymphoid cells.

The specific dose of Lenalidomid Piramal is determined by the prescribing clinician based on the patient’s diagnosis, disease stage, renal function, and other individual factors. Healthcare professionals follow approved labeling and clinical guidelines to set an appropriate regimen.

Lenalidomid Piramal is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal harm. Women of childbearing potential must use effective contraception, and breastfeeding is not recommended while taking the medication.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both lenalidomide and thalidomide belong to the immunomodulatory drug class, but lenalidomide is more potent, has a broader spectrum of activity, and generally exhibits a more favorable safety profile, especially regarding peripheral neuropathy. Clinical guidelines often prefer lenalidomide for the approved indications listed.

Lenalidomid Piramal should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains sealed until use.

The medication is taken orally, usually as a tablet, with or without food as directed by the prescriber. Patients should swallow the tablet whole and follow the dosing schedule provided by their healthcare professional.

Serious risks include venous thromboembolism, severe neutropenia leading to infection, secondary primary malignancies, and rare but severe skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored closely for signs of these events and report any concerning symptoms promptly.

Lenalidomid Piramal is contraindicated in pregnant women, individuals with known hypersensitivity to lenalidomide or its excipients, and patients with uncontrolled severe infections. Caution is also advised for those with significant renal or hepatic impairment, and the drug should be avoided in patients receiving live vaccines.